Ishares Pharmaceuticals Etf Performance
| IHE Etf | USD 68.80 0.34 0.50% |
The etf retains a Market Volatility (i.e., Beta) of 0.15, which attests to not very significant fluctuations relative to the market. As returns on the market increase, IShares Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding IShares Pharmaceuticals is expected to be smaller as well.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days iShares Pharmaceuticals ETF has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical indicators, IShares Pharmaceuticals is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| In Threey Sharp Ratio | 0.15 |
IShares |
IShares Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,186 in iShares Pharmaceuticals ETF on August 29, 2024 and sell it today you would lose (306.00) from holding iShares Pharmaceuticals ETF or give up 4.26% of portfolio value over 90 days. iShares Pharmaceuticals ETF is generating negative expected returns assuming volatility of 0.7293% on return distribution over 90 days investment horizon. In other words, 6% of etfs are less volatile than IShares, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
IShares Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IShares Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as iShares Pharmaceuticals ETF, and traders can use it to determine the average amount a IShares Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0896
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IHE |
Estimated Market Risk
| 0.73 actual daily | 6 94% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IShares Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IShares Pharmaceuticals by adding IShares Pharmaceuticals to a well-diversified portfolio.
IShares Pharmaceuticals Fundamentals Growth
IShares Etf prices reflect investors' perceptions of the future prospects and financial health of IShares Pharmaceuticals, and IShares Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IShares Etf performance.
| Price To Earning | 22.36 X | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 3.32 X | |||
| Total Asset | 381.08 M | |||
About IShares Pharmaceuticals Performance
By analyzing IShares Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into IShares Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IShares Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IShares Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
The fund generally will invest at least 80 percent of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. US Pharmaceuticals is traded on NYSEARCA Exchange in the United States.| IShares Pharmaceuticals generated a negative expected return over the last 90 days | |
| The fund retains 99.89% of its assets under management (AUM) in equities |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.